• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

弥漫性大B细胞淋巴瘤的管理特征与结果:科特迪瓦的经验

Characteristics and Results of the Management of Diffuse Large B-Cell Lymphomas: The Experience of Côte d'Ivoire.

作者信息

Tolo Diebkilé Aïssata, Kouakou Boidy, N'dhatz Emeraude, Nanho Clotaire D, Meité N'dogomo, Ayémou Roméo, Sekongo Mamadou Y, Kouéhion Paul, Konan Mozart, Koffi Gustave K, Sanogo Ibrahima

机构信息

Department of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'Ivoire.

出版信息

Adv Hematol. 2012;2012:945138. doi: 10.1155/2012/945138. Epub 2012 May 28.

DOI:10.1155/2012/945138
PMID:22693514
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3368158/
Abstract

Diffuse large B-cell lymphomas have been little studied in black Africans. The purpose of our study was to determine the characteristics and results of the management of these lymphomas. Patients and Methods. In a descriptive and analytic retrospective study we studied the medical records of 63 patients with diffuse large B-cell lymphoma hospitalized during the period from 1991 to 2007. The diagnosis was made after lymph node or organ biopsy. Response to treatment, OS, PFS, and toxicity were studied. The complete response has been analyzed univariate and multivariate analysis. Results. The median age was 42 years. The sex ratio was 2. The HIV serology was positive in 11 cases, and 8 patients had antiretroviral therapy. In 71% the lymphoma was at stages III and IV of Ann Arbor. IPI was ≥3 in 65%. Complete remission was achieved in 43%. Only 43% of patients had had a good compliance. Progression-free survival at 3 years was 32%, and overall survival at 3 years was 50%. 13% of patients were lost to follow up, and 51% of them died. In terms of analysis the complete remission rate was influenced by the stage of Ann Arbor (P < 0.0001), biological b symptoms (P < 0.01), the IPI (P < 0.0001), and the socioeconomic standing (P = 0.001). In multivariate analysis, only IPI and stage of Ann Arbor influence the complete remission.

摘要

在非洲黑人中,弥漫性大B细胞淋巴瘤的研究较少。我们研究的目的是确定这些淋巴瘤的特征及治疗结果。患者与方法。在一项描述性和分析性回顾性研究中,我们研究了1991年至2007年期间住院的63例弥漫性大B细胞淋巴瘤患者的病历。诊断通过淋巴结或器官活检做出。研究了治疗反应、总生存期(OS)、无进展生存期(PFS)和毒性。对完全缓解进行了单因素和多因素分析。结果。中位年龄为42岁。男女比例为2。11例患者HIV血清学呈阳性,8例患者接受了抗逆转录病毒治疗。71%的淋巴瘤处于Ann Arbor分期的III期和IV期。65%的患者国际预后指数(IPI)≥3。43%的患者实现了完全缓解。只有43%的患者依从性良好。3年无进展生存率为32%,3年总生存率为50%。13%的患者失访,其中51%死亡。在分析方面,完全缓解率受Ann Arbor分期(P < 0.0001)、生物学B症状(P < 0.01)、IPI(P < 0.0001)和社会经济地位(P = 0.001)影响。在多因素分析中,只有IPI和Ann Arbor分期影响完全缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bca/3368158/940e87cd99ed/AH2012-945138.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bca/3368158/940e87cd99ed/AH2012-945138.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bca/3368158/940e87cd99ed/AH2012-945138.001.jpg

相似文献

1
Characteristics and Results of the Management of Diffuse Large B-Cell Lymphomas: The Experience of Côte d'Ivoire.弥漫性大B细胞淋巴瘤的管理特征与结果:科特迪瓦的经验
Adv Hematol. 2012;2012:945138. doi: 10.1155/2012/945138. Epub 2012 May 28.
2
[Prognosis analysis of primary breast diffuse large B cell lymphoma].[原发性乳腺弥漫性大B细胞淋巴瘤的预后分析]
Zhonghua Zhong Liu Za Zhi. 2019 Mar 23;41(3):235-240. doi: 10.3760/cma.j.issn.0253-3766.2019.03.015.
3
Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era.利妥昔单抗时代原发性韦氏环和淋巴结弥漫性大B细胞淋巴瘤的临床特征与预后
Leuk Res. 2017 Sep;60:89-93. doi: 10.1016/j.leukres.2017.07.006. Epub 2017 Jul 25.
4
[Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience].
Bull Cancer. 2007 Oct;94(10):902-6.
5
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.口颌面部头颈部黏膜相关淋巴组织结外边缘区 B 细胞淋巴瘤:105 例回顾性分析。
Cancer Med. 2020 Jan;9(1):194-203. doi: 10.1002/cam4.2681. Epub 2019 Nov 15.
6
[Analysis for clinicopathological features, therapy and prognosis of 30 elderly patients with non-Hodgkin's lymphoma].30例老年非霍奇金淋巴瘤患者的临床病理特征、治疗及预后分析
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Dec;21(6):1464-70. doi: 10.7534/j.issn.1009-2137.2013.06.018.
7
[Prognostic analysis of 525 Chinese patients with diffuse large B cell lymphoma].[525例中国弥漫性大B细胞淋巴瘤患者的预后分析]
Beijing Da Xue Xue Bao Yi Xue Ban. 2014 Jun 18;46(3):405-11.
8
Adult primary testicular lymphoma: clinical features and survival in a series of patients treated at a high-volume institution in China.成人原发性睾丸淋巴瘤:在中国一家大容量机构治疗的一系列患者中的临床特征和生存情况。
BMC Cancer. 2020 Mar 14;20(1):220. doi: 10.1186/s12885-020-6711-0.
9
The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum.I期和II期原发性纵隔大B细胞淋巴瘤综合治疗的结果。
Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1281-5. doi: 10.1016/s0360-3016(00)00563-0.
10
Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.弥漫大 B 细胞淋巴瘤患者接受 R-CHOP 样或 CHOP 样方案治疗的临床特征和结局:单中心 8 年经验。
Ann Palliat Med. 2020 Jul;9(4):1442-1452. doi: 10.21037/apm-19-589. Epub 2020 Jul 2.

引用本文的文献

1
A Pilot Collaborative Study to Improve the Diagnosis and Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in Senegal: The LYMPHODAK Study.一项旨在改善塞内加尔新诊断弥漫性大B细胞淋巴瘤患者诊断与治疗的试点合作研究:LYMPHODAK研究。
EJHaem. 2025 Aug 12;6(4):e70133. doi: 10.1002/jha2.70133. eCollection 2025 Aug.
2
Scaffold-mediated switching of lymphoma metabolism in culture.支架介导的培养中淋巴瘤代谢转换
Cancer Metab. 2022 Oct 12;10(1):15. doi: 10.1186/s40170-022-00291-y.
3
Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.

本文引用的文献

1
Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma.对于原发性结外弥漫性大B细胞淋巴瘤患者,在CHOP方案中添加利妥昔单抗并无益处。
Korean J Hematol. 2011 Jun;46(2):103-10. doi: 10.5045/kjh.2011.46.2.103. Epub 2011 Jun 21.
2
Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era.弥漫大 B 细胞淋巴瘤患者在利妥昔单抗时代的干细胞移植。
Curr Opin Oncol. 2011 Mar;23(2):209-13. doi: 10.1097/CCO.0b013e328342b8ad.
3
Improving outcomes for patients with diffuse large B-cell lymphoma.
抗体药物偶联物的临床前到临床转化:基于药代动力学/药效动力学模型的伊妥珠单抗奥滨尤妥珠单抗回顾性分析。
AAPS J. 2016 Sep;18(5):1101-1116. doi: 10.1208/s12248-016-9929-7. Epub 2016 May 19.
提高弥漫性大 B 细胞淋巴瘤患者的治疗效果。
CA Cancer J Clin. 2010 Nov-Dec;60(6):393-408. doi: 10.3322/caac.20087. Epub 2010 Oct 28.
4
Front-line management of diffuse large B cell lymphoma.弥漫性大 B 细胞淋巴瘤的一线治疗。
Curr Opin Oncol. 2010 Nov;22(6):642-5. doi: 10.1097/CCO.0b013e32833ed848.
5
Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.弥漫性大B细胞非霍奇金淋巴瘤:ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2010 May;21 Suppl 5:v172-4. doi: 10.1093/annonc/mdq203.
6
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.LNH-98.5 试验患者的长期预后,这是第一项比较利妥昔单抗-CHOP 与 DLBCL 患者标准 CHOP 化疗的随机研究:成人淋巴瘤研究组的一项研究。
Blood. 2010 Sep 23;116(12):2040-5. doi: 10.1182/blood-2010-03-276246. Epub 2010 Jun 14.
7
First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions.CD20+弥漫性大B细胞淋巴瘤的一线治疗:事实与未决问题。
Haematologica. 2009 Sep;94(9):1194-8. doi: 10.3324/haematol.2009.011320.
8
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.对于接受R-CHOP治疗的弥漫性大B细胞淋巴瘤患者,修订后的国际预后指数(R-IPI)比标准IPI能更好地预测预后。
Blood. 2007 Mar 1;109(5):1857-61. doi: 10.1182/blood-2006-08-038257. Epub 2006 Nov 14.
9
Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification.弥漫性大B细胞淋巴瘤:是一种还是多种实体?当前的争议及可能的亚分类方法
Histopathology. 2002 Dec;41(6):482-509. doi: 10.1046/j.1365-2559.2002.01538.x.
10
Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy.
Blood. 2000 Oct 15;96(8):2730-4.